WAVE Life Sciences Reports Q2 2025 Earnings: RNA Editing Progress Amid Revenue Decline and Strong Cash Position

WAVE Life Sciences reported a decline in Q2 2025 revenue to $8.7 million from $19.7 million in the prior year quarter. However, the company made significant progress in RNA editing, including positive data from their AATD clinical program and Eli clinical program for obesity. They also have a strong cash position, with $208.5 million expected to fund operations into 2027.

Wave Life Sciences Ltd. (NASDAQ: WVE) reported a decline in Q2 2025 revenue to $8.7 million, down from $19.7 million in the prior year quarter, according to earnings released on July 30, 2025 [2]. The company's net loss widened to $50.5 million, compared to a net loss of $32.9 million in the same period last year [2]. Despite the financial setbacks, Wave Life Sciences has made significant progress in RNA editing, particularly with their AATD clinical program and Eli clinical program for obesity [2].

The company delivered positive data from their forward 53 clinical trial of N531 for DMD, showing statistically significant improvements [2]. Additionally, WVE 006, their RNA editing oligonucleotide for alpha one antitrypsin deficiency, demonstrated impressive durability and a favorable safety profile [2]. Wave Life Sciences has expanded its second cohort for the WVE 007 obesity program due to favorable safety and robust active reduction [2].

Wave Life Sciences maintains a strong cash position, with $208.5 million in cash and cash equivalents, expected to fund operations into 2027 [2]. The company's cash position supports ongoing clinical-stage biotechnology initiatives and the advancement of key clinical programs [1].

The CEO, Paul Bolno, expressed optimism regarding the RestorAATion-2 study's progress and the therapeutic potential of WVE-006. He highlighted anticipated positive clinical outcomes and robust execution, positioning Wave Life Sciences for future success [1].

Wave Life Sciences plans to release multi-dose data from the RestorAATion-2 trial in Q3 2025, followed by single-dose data in Fall 2025. Data from Cohort 2 of the INLIGHT trial are expected in Q4 2025, with Cohort 3 data projected for Q1 2026 [1].

References:
[1] https://www.ainvest.com/news/wave-life-sciences-2025-q2-earnings-revenue-drops-56-net-loss-widens-2507/
[2] https://ca.finance.yahoo.com/news/wave-life-sciences-ltd-wve-090121974.html